Haleon (LON:HLN) Stock Price Up 0.1% – What’s Next?

Haleon plc (LON:HLN)’s stock price traded up 0.1% during mid-day trading on Wednesday. The stock traded as high as GBX 341.70 and last traded at GBX 337.60. Approximately 2,147,000,000 shares changed hands during mid-day trading, an increase of 5,457% from the average daily volume of 38,634,129 shares. The stock had previously closed at GBX 337.10.

Analysts Set New Price Targets

Several brokerages have commented on HLN. Royal Bank Of Canada raised their price objective on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. cut their price objective on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Berenberg Bank lifted their target price on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 400 target price on shares of Haleon in a research note on Friday, July 31st. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Haleon from GBX 335 to GBX 320 and set a “sell” rating on the stock in a report on Wednesday, September 9th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of GBX 387.80.

Haleon Stock Performance

The business’s fifty day moving average price is GBX 355.23 and its 200-day moving average price is GBX 352.73. The company has a debt-to-equity ratio of 50.38, a quick ratio of 0.93 and a current ratio of 0.69. The stock has a market cap of £28.87 billion, a PE ratio of 18.14, a P/E/G ratio of 1.49 and a beta of 0.24.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. As a group, equities research analysts forecast that Haleon plc will post 19.5033282 EPS for the current fiscal year.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.